BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF17), is an attractive therapeutic target in MM, due to high surface expression on malignant plasma cells but not on normal tissues [8, 9]. Here, TNFRSF17 is linked to Miyoshi myopathy.